These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 16482237)

  • 1. Predictors of antiviral therapy in a post-transfusion cohort of hepatitis C patients.
    Witkos M; Yi QL; Heathcote J; Kapral MK; Krahn MD
    Can J Gastroenterol; 2006 Feb; 20(2):107-11. PubMed ID: 16482237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiviral regimen complexity index as an independent predictor of sustained virologic response in patients with chronic hepatitis C.
    Galán RJ; Cidoncha EC; Martin MF; Rodriguez CC; Almeida CV; Verdugo RM
    J Manag Care Pharm; 2013; 19(6):448-53. PubMed ID: 23806058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon-based hepatitis C therapy in a safety net hospital: access, efficacy, and safety.
    Nordstrom EM; Keniston A; Baouchi F; Martinez-Camacho A
    Eur J Gastroenterol Hepatol; 2017 Jan; 29(1):10-16. PubMed ID: 27755117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response predictors and clinical benefits of hepatitis C retreatment with pegylated interferon and ribavirin in HIV/HCV coinfection.
    Peribañez-Gonzalez M; da Silva MH; Vilar FC; Seixas-Santos Nastri AC; Ferreira PA; Focaccia R; Mendes Correa MC
    Ann Hepatol; 2013; 12(2):228-35. PubMed ID: 23396734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In routine clinical practice, few physicians use early viral kinetics to guide HCV dual therapy treatment decisions.
    Mangia A; Bányai T; De Bartolomeo G; Gervain J; Habersetzer F; Mulkay JP; Ouzan D; Parruti G; Passariello N; Remy AJ; Rizzetto M; Shiffman ML; Tice AD; Schmitz M; Tatsch F; Rodriguez-Torres M
    Liver Int; 2014 Aug; 34(7):e217-28. PubMed ID: 24251988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Efficacy and safety of pegylated-interferon plus ribavirin in HIV-infected patients co-infected with hepatitis C virus in clinical practice: a 32 cases observational follow-up].
    Seydi M; Morlat P; Bonnet F; Rambeloarisoa J; Bernard N; Lacoste D; Bonarek M; Trimoulet P; Ramanampamonjy R; Lafon ME; Dramé M; Beylot J
    Rev Med Interne; 2005 Apr; 26(4):280-7. PubMed ID: 15820563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sexually transmitted acute infection with a clustered genotype 4 hepatitis C virus in HIV-1-infected men and inefficacy of early antiviral therapy.
    Serpaggi J; Chaix ML; Batisse D; Dupont C; Vallet-Pichard A; Fontaine H; Viard JP; Piketty C; Rouveix E; Rouzioux C; Weiss L; Pol S
    AIDS; 2006 Jan; 20(2):233-40. PubMed ID: 16511416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Access to New Medications for Hepatitis C for Medicaid Members: A Retrospective Cohort Study.
    Clements KM; Clark RE; Lavitas P; Kunte P; Graham CS; O'Connell E; Lenz K; Jeffrey P
    J Manag Care Spec Pharm; 2016 Jun; 22(6):714-722b. PubMed ID: 27231798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. INCIDENCE OF TUBERCULOSIS AMONG HIV/HCV CO-INFECTED PATIENTS RECEIVING HEPATITIS C TREATMENT WITH PEGYLATED INTERFERON AND RIBAVIRIN IN GEORGIA.
    Abutidze A; Bolokadze N; Chkhartishvili N; Sharvadze L; Tsertsvadze T
    Georgian Med News; 2016 Mar; (252):10-5. PubMed ID: 27119828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis C virus genotype 1 in HIV-HCV co-infected patients: final results of the Spanish BOC HIV-HCV Study.
    Laguno M; Von Wichmann MA; Van den Eynde E; Navarro J; Cifuentes C; Murillas J; Veloso S; Martínez-Rebollar M; Guardiola JM; Jou A; Gómez-Sirvent JL; Cervantes M; Pineda JA; López-Calvo S; Carrero A; Montes ML; Deig E; Tapiz A; Ruiz-Mesa JD; Cruceta A; de Lazzari E; Mallolas J
    Int J Infect Dis; 2016 Dec; 53():46-51. PubMed ID: 27815225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NIH Consensus Statement on Management of Hepatitis C: 2002.
    NIH Consens State Sci Statements; 2002 Jun 10-12; 19(3):1-46. PubMed ID: 14768714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of Smoking on Pegylated Interferon alpha 2a and First Generation Protease Inhibitor-based Antiviral Therapy in Naïve Patients Infected with Hepatitis C Virus Genotype 1.
    Zimmermann T; Hueppe D; Mauss S; Buggisch P; Pfeiffer-Vornkahl H; Grimm D; Galle PR; Alshuth U
    J Gastrointestin Liver Dis; 2016 Mar; 25(1):15-24. PubMed ID: 27014750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Indications for interferon/ribavirin therapy in hepatitis C patients: findings from a survey of Canadian hepatologists.
    Wang P; Yi Q; Scully L; Heathcote J; Krahn M
    Can J Gastroenterol; 2003 Mar; 17(3):183-6. PubMed ID: 12677268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of All-Oral Antiviral Regimens in 996 Human Immunodeficiency Virus/Hepatitis C Virus Genotype 1-Coinfected Patients Treated in Routine Practice.
    Bhattacharya D; Belperio PS; Shahoumian TA; Loomis TP; Goetz MB; Mole LA; Backus LI
    Clin Infect Dis; 2017 Jun; 64(12):1711-1720. PubMed ID: 28199525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Barriers to hepatitis C virus treatment in a Canadian HIV-hepatitis C virus coinfection tertiary care clinic.
    McLaren M; Garber G; Cooper C
    Can J Gastroenterol; 2008 Feb; 22(2):133-7. PubMed ID: 18299730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health-related quality of life and severity of fatigue in HIV/HCV co-infected patients before, during, and after antiviral therapy with pegylated interferon plus ribavirin.
    Mandorfer M; Payer BA; Scheiner B; Breitenecker F; Aichelburg MC; Grabmeier-Pfistershammer K; Rieger A; Trauner M; Peck-Radosavljevic M; Reiberger T
    Liver Int; 2014 Jan; 34(1):69-77. PubMed ID: 23890125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gaps in hepatitis C virus prevention and care for HIV-hepatitis C virus co-infected people who inject drugs in Canada.
    Lanièce Delaunay C; Maheu-Giroux M; Marathe G; Saeed S; Martel-Laferrière V; Cooper CL; Walmsley S; Cox J; Wong A; Klein MB;
    Int J Drug Policy; 2022 May; 103():103627. PubMed ID: 35218989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis C Virus Infection Outcomes Among Immigrants to Canada: A Retrospective Cohort Analysis.
    Cooper CL; Thavorn K; Damian E; Corsi DJ
    Ann Hepatol; 2017; 16(5):720-726. PubMed ID: 28809741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Virological response in patients with hepatitis C virus genotype 1b and a high viral load: impact of peginterferon-alpha-2a plus ribavirin dose reductions and host-related factors.
    Yamada G; Iino S; Okuno T; Omata M; Kiyosawa K; Kumada H; Hayashi N; Sakai T
    Clin Drug Investig; 2008; 28(1):9-16. PubMed ID: 18081356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Appendix: The National Institutes of Health Consensus Development Conference Management of Hepatitis C 2002.
    Seeff LB; Hoofnagle JH
    Clin Liver Dis; 2003 Feb; 7(1):261-87. PubMed ID: 12691470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.